MCM3 upregulation confers endocrine resistance in breast cancer and is a predictive marker of diminished tamoxifen benefit

Sanne Løkkegaard, Daniel Elias, Carla L. Alves, Martin V. Bennetzen, Anne Vibeke Lænkholm, Martin Bak, Morten F. Gjerstorff, Lene E. Johansen, Henriette Vever, Christina Bjerre, Tove Kirkegaard, Bo Nordenskjöld, Tommy Fornander, Olle Stål, Linda S. Lindström, Laura J. Esserman, Anne E. Lykkesfeldt, Jens S. Andersen, Rikke Leth-Larsen, Henrik J. Ditzel*

*Corresponding author for this work

Research output: Contribution to journalJournal articleResearchpeer-review

1 Downloads (Pure)

Fingerprint Dive into the research topics of 'MCM3 upregulation confers endocrine resistance in breast cancer and is a predictive marker of diminished tamoxifen benefit'. Together they form a unique fingerprint.

Medicine & Life Sciences